NRX Pharmaceuticals, Inc. Logo

NRX Pharmaceuticals, Inc.

Develops novel oral drugs for CNS disorders, targeting suicidal depression and PTSD.

NRXP | US

Overview

Corporate Details

ISIN(s):
US0894821034 (+2 more)
LEI:
Country:
United States of America
Address:
1201 ORANGE STREET, 19801 WILMINGTON
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics for central nervous system (CNS) disorders. The company is focused on addressing the high unmet medical need for treatments for severe bipolar depression and Post-Traumatic Stress Disorder (PTSD), particularly in patients with suicidal ideation. Its lead candidate, NRX-101, is the first investigational oral medication in FDA trials for suicidal bipolar depression and has received Fast Track and Breakthrough Therapy designations. The company's scientific platform is based on targeting the brain's NMDA receptor with a non-hallucinogenic, non-addictive approach. Its pipeline also includes KETAFREE™, a preservative-free ketamine product for suicidal depression.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all NRX Pharmaceuticals, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for NRX Pharmaceuticals, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for NRX Pharmaceuticals, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Japan Tissue Engineering Co., Ltd. Logo
Pioneers regenerative medicine with tissue products, CDMO services, and research models.
Japan 7774
Jasper Therapeutics, Inc. Logo
Develops mast cell-depleting antibody therapies for chronic diseases and stem cell transplants.
United States of America JSPR
Jazz Pharmaceuticals plc Logo
Develops medicines for serious diseases in neuroscience and oncology.
United States of America JAZZ
Develops therapies for rare genetic diseases, CNS disorders, and regenerative medicine.
Japan 4552
JEIL PHARMACEUTICAL CO.,LTD Logo
Global manufacturer of pharmaceutical APIs, antibiotics, and injection-based treatments.
South Korea 271980
JEIL PHARMA HOLDINGS INC. Logo
Develops and distributes APIs, generics, and modified drugs, specializing in injections.
South Korea 002620
JETEMA Co.,Ltd. Logo
Research-driven developer of aesthetic toxins, dermal fillers, and threads.
South Korea 216080
Develops and manufactures high-tech drugs for cancer, diabetes, and a range of diseases.
South Korea 007370
JOHNSON & JOHNSON Logo
Develops innovative medicines and medical technologies for complex diseases and personalized care.
United States of America JNJ
Journey Medical Corp Logo
A pharmaceutical firm commercializing prescription drugs and generics for dermatology.
United States of America DERM

Talk to a Data Expert

Have a question? We'll get back to you promptly.